JP5711352B2 - マクロライドの結晶形、およびその使用 - Google Patents

マクロライドの結晶形、およびその使用 Download PDF

Info

Publication number
JP5711352B2
JP5711352B2 JP2013501396A JP2013501396A JP5711352B2 JP 5711352 B2 JP5711352 B2 JP 5711352B2 JP 2013501396 A JP2013501396 A JP 2013501396A JP 2013501396 A JP2013501396 A JP 2013501396A JP 5711352 B2 JP5711352 B2 JP 5711352B2
Authority
JP
Japan
Prior art keywords
cem
crystal form
composition
ray powder
powder diffraction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013501396A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013522367A (ja
JP2013522367A5 (OSRAM
Inventor
ペレイラ，デービッド，イー．
Original Assignee
センプラ ファーマシューティカルズ，インコーポレイテッド
センプラ ファーマシューティカルズ，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44673574&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5711352(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by センプラ ファーマシューティカルズ，インコーポレイテッド, センプラ ファーマシューティカルズ，インコーポレイテッド filed Critical センプラ ファーマシューティカルズ，インコーポレイテッド
Publication of JP2013522367A publication Critical patent/JP2013522367A/ja
Publication of JP2013522367A5 publication Critical patent/JP2013522367A5/ja
Application granted granted Critical
Publication of JP5711352B2 publication Critical patent/JP5711352B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2013501396A 2010-03-22 2011-03-22 マクロライドの結晶形、およびその使用 Active JP5711352B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31606310P 2010-03-22 2010-03-22
US61/316,063 2010-03-22
PCT/US2011/029424 WO2011119604A1 (en) 2010-03-22 2011-03-22 Crystalline forms of a macrolide, and uses therefor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014231987A Division JP6121387B2 (ja) 2010-03-22 2014-11-14 マクロライドの結晶形、およびその使用

Publications (3)

Publication Number Publication Date
JP2013522367A JP2013522367A (ja) 2013-06-13
JP2013522367A5 JP2013522367A5 (OSRAM) 2014-05-15
JP5711352B2 true JP5711352B2 (ja) 2015-04-30

Family

ID=44673574

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2013501396A Active JP5711352B2 (ja) 2010-03-22 2011-03-22 マクロライドの結晶形、およびその使用
JP2014231987A Active JP6121387B2 (ja) 2010-03-22 2014-11-14 マクロライドの結晶形、およびその使用
JP2016244733A Pending JP2017081953A (ja) 2010-03-22 2016-12-16 マクロライドの結晶形、およびその使用
JP2019163614A Pending JP2020002168A (ja) 2010-03-22 2019-09-09 マクロライドの結晶形、およびその使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2014231987A Active JP6121387B2 (ja) 2010-03-22 2014-11-14 マクロライドの結晶形、およびその使用
JP2016244733A Pending JP2017081953A (ja) 2010-03-22 2016-12-16 マクロライドの結晶形、およびその使用
JP2019163614A Pending JP2020002168A (ja) 2010-03-22 2019-09-09 マクロライドの結晶形、およびその使用

Country Status (19)

Country Link
US (4) US8975386B2 (OSRAM)
EP (2) EP3009442B1 (OSRAM)
JP (4) JP5711352B2 (OSRAM)
KR (2) KR20180101643A (OSRAM)
CN (2) CN103080122A (OSRAM)
AU (2) AU2011232627B2 (OSRAM)
BR (1) BR112012023950A2 (OSRAM)
CA (1) CA2793884C (OSRAM)
DK (1) DK2550286T3 (OSRAM)
ES (1) ES2564097T3 (OSRAM)
HR (1) HRP20160168T1 (OSRAM)
IL (1) IL222018B (OSRAM)
MX (1) MX361413B (OSRAM)
MY (1) MY162411A (OSRAM)
NZ (1) NZ602544A (OSRAM)
PL (1) PL2550286T3 (OSRAM)
RU (1) RU2650883C2 (OSRAM)
SI (1) SI2550286T1 (OSRAM)
WO (1) WO2011119604A1 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017081953A (ja) * 2010-03-22 2017-05-18 センプラ ファーマシューティカルズ，インコーポレイテッド マクロライドの結晶形、およびその使用

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2529817C (en) 2003-03-10 2013-02-12 Optimer Pharmaceuticals, Inc. Novel antibacterial agents
AU2008316830B2 (en) 2007-10-25 2016-03-17 Cempra Pharmaceuticals, Inc. Process for the preparation of macrolide antibacterial agents
WO2010048600A1 (en) 2008-10-24 2010-04-29 Cempra Pharmaceuticals, Inc. Methods for treating resistant diseases using triazole containing macrolides
US9937194B1 (en) 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
US9480679B2 (en) 2009-09-10 2016-11-01 Cempra Pharmaceuticals, Inc. Methods for treating malaria, tuberculosis and MAC diseases
EP2571506B1 (en) 2010-05-20 2017-05-10 Cempra Pharmaceuticals, Inc. Processes for preparing macrolides and ketolides and intermediates therefor
KR20130120458A (ko) 2010-09-10 2013-11-04 셈프라 파마슈티컬스, 인크. 질환을 치료하기 위한 수소결합 형성 플루오로 케토라이드
WO2013148891A1 (en) 2012-03-27 2013-10-03 Cempra Pharmaceuticals, Inc. Parenteral formulations for administering macrolide antibiotics
EP2968801B1 (en) 2013-03-14 2018-09-26 Cempra Pharmaceuticals, Inc. Methods for treating respiratory diseases and formulations therefor
MX356772B (es) 2013-03-15 2018-06-13 Cempra Pharmaceuticals Inc Procesos convergentes para la preparacion de agentes antibacterianos macrolidos.
CN105246334A (zh) 2013-04-04 2016-01-13 哈佛大学的校长及成员们 大环内酯及其制备和使用方法
CN106604729A (zh) * 2014-08-05 2017-04-26 森普拉制药公司 抗菌剂的粉末口服混悬制剂
CN104151382B (zh) * 2014-08-08 2016-09-14 广东东阳光药业有限公司 一种固态大环内酯的晶型
CN104311611B (zh) * 2014-08-13 2017-01-18 广东东阳光药业有限公司 一种制备固态大环内酯的方法
HK1242920A1 (zh) 2014-10-08 2018-07-06 哈佛大学的校长及成员们 14-元酮内酯及其制备和使用方法
WO2016154591A1 (en) 2015-03-25 2016-09-29 President And Fellows Of Harvard College Macrolides with modified desosamine sugars and uses thereof
JP6112696B1 (ja) * 2015-10-05 2017-04-12 富山化学工業株式会社 ソリスロマイシンを含む錠剤
EP3190122A1 (en) * 2016-01-08 2017-07-12 LEK Pharmaceuticals d.d. A novel synthetic pathway towards solithromycin and purification thereof
WO2018045294A1 (en) * 2016-09-02 2018-03-08 Cempra Pharmaceuticals, Inc. Processes for preparing fluoroketolides
AU2020395150A1 (en) * 2019-12-02 2022-06-23 AliquantumRx, Inc. Salts and polymorphs of cethromycin for the treatment of disease salts and polymorphs of cethromycin

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331803A (en) 1980-06-04 1982-05-25 Taisho Pharmaceutical Co., Ltd. Novel erythromycin compounds
US4474768A (en) 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
US4742049A (en) 1986-06-04 1988-05-03 Abbott Laboratories Semisynthetic erythromycin antibiotics
IL114589A (en) 1990-11-21 1999-12-22 Roussel Uclaf Intermediates for the preparation of erythromycin derivatives
US5985844A (en) 1992-03-26 1999-11-16 Merck & Co., Inc. Homoerythromycin A derivatives modified at the 4"-and 8A-positions
US5527780A (en) 1992-11-05 1996-06-18 Roussel Uclaf Erythromycin derivatives
FR2697524B1 (fr) 1992-11-05 1994-12-23 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
FR2718450B1 (fr) 1994-04-08 1997-01-10 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
FR2719587B1 (fr) 1994-05-03 1996-07-12 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
US5834428A (en) 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
FR2739620B1 (fr) 1995-10-09 1997-12-19 Roussel Uclaf Nouveaux derives de la 5-0-desosaminyl 6-o-methyl erythronolide a, leur procede de preparation et leur application a la preparation de produits biologiquement actifs
US6274715B1 (en) 1995-11-08 2001-08-14 Abbott Laboratories Tricyclic erythromycin derivatives
FR2742757B1 (fr) 1995-12-22 1998-01-30 Roussel Uclaf Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
FR2745290B1 (fr) 1996-02-28 1998-04-03 Roussel Uclaf Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
EP1291351B1 (en) 1996-09-04 2005-07-13 Abbott Laboratories 6-0 substituted ketolides having antibacterial activity
US6407074B1 (en) 1997-06-11 2002-06-18 Pfizer Inc C-4″-substituted macrolide derivatives
HN1998000086A (es) 1997-06-11 1999-03-08 Pfizer Prod Inc Derivados de 9 - desofo - 9 aza - 9a - homoeritromicina a - c - 4 sustituidos.
PL337606A1 (en) 1997-06-11 2000-08-28 Pfizer Prod Inc Derivatives of erythromycin 9-oxime
HN1998000159A (es) 1997-10-29 1999-02-09 Monsanto Co Derivados de 9- amino - 3 ceto eritromicina
IL135792A0 (en) 1997-12-01 2001-05-20 Abbott Lab 6-o-alkyl derivatives of erythronolide b
FR2777282B1 (fr) 1998-04-08 2001-04-20 Hoechst Marion Roussel Inc Nouveaux derives de la 2-fluoro 3-de((2,6-dideoxy 3-c-methyl 3-0-methyl-alpha-l-ribohexopyranosyl) oxyl) 6-o-methyl 3-oxo erythromycine, leur procede de preparation et leur application a la synthese de principes actifs de medicaments
US6020521A (en) 1998-08-26 2000-02-01 Abbott Laboratories Macrolide LHRH antagonists
US6387885B1 (en) 1998-08-26 2002-05-14 Abbott Laboratories 3′,3′-N-bis-desmethyl-3′-N-cycloalkyl erythromycin derivatives as LHRH antagonists
FR2785612A1 (fr) 1998-11-10 2000-05-12 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
FR2786188B1 (fr) 1998-11-24 2002-10-31 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur applicaion comme medicaments
KR100317907B1 (ko) 1998-11-24 2001-12-24 김 완 주 신규한 중간체, 이를 이용한 마크로라이드계 항생제의제조방법
AU6484199A (en) 1998-12-10 2000-06-26 Pfizer Products Inc. Carbamate and carbazate ketolide antibiotics
OA11753A (en) 1999-01-27 2005-07-19 Pfizer Prod Inc Ketolide antibiotics.
CA2292359C (en) 1999-01-28 2004-09-28 Pfizer Products Inc. Novel azalides and methods of making same
US6395710B1 (en) 1999-04-16 2002-05-28 Kosan Biosciences, Inc. Macrolide antiinfective agents
CN1373767A (zh) 1999-04-16 2002-10-09 奥索-麦克尼尔药品公司 酮式大环内酯抗菌剂
US6420535B1 (en) 1999-06-07 2002-07-16 Abbott Laboratories 6-O-carbamate ketolide derivatives
US6437106B1 (en) 1999-06-24 2002-08-20 Abbott Laboratories Process for preparing 6-o-substituted erythromycin derivatives
WO2001010878A1 (fr) 1999-08-06 2001-02-15 Taisho Pharmaceutical Co., Ltd. Derives d'erythromycine a
KR100336447B1 (ko) 1999-11-24 2002-05-15 민경윤 클라리스로마이신의 개선된 제조방법
JP2001261694A (ja) 2000-03-06 2001-09-26 Pfizer Prod Inc ケトライド抗生物質
DE60122791T2 (de) 2000-03-15 2007-10-04 Hanmi Pharm. Co., Ltd. Verfahren zur Herstellung von Clarythromycin mit nicht pharmazeutischer Qualität
US20020115621A1 (en) 2000-08-07 2002-08-22 Wei-Gu Su Macrolide antibiotics
GB0031312D0 (en) 2000-12-21 2001-02-07 Glaxo Group Ltd Macrolides
PT1320355E (pt) 2001-05-18 2006-08-31 Chiron Corp Sistema para administracao de uma formulacao de tobramicina
CA2451391A1 (en) 2001-07-03 2003-01-16 Chiron Corporation C12 modified erythromycin macrolides and ketolides having antibacterial activity
US20030176327A1 (en) 2001-10-25 2003-09-18 Cassell Gail Houston Antibiotics for treating biohazardous bacterial agents
AU2003218059A1 (en) 2002-02-22 2003-09-09 Pharmacia Corporation Ophthalmic antibiotic drug formulations containing a cyclodextrin compound and cetyl pyridinium chloride
ATE469135T1 (de) 2002-05-30 2010-06-15 Scripps Research Inst Kupferkatalysierte ligierung von aziden und acetylenen
AR043050A1 (es) 2002-09-26 2005-07-13 Rib X Pharmaceuticals Inc Compuestos heterociclicos bifuncionales y metodos para preparar y usar los mismos
ITMI20022292A1 (it) 2002-10-29 2004-04-30 Zambon Spa 9a-azalidi ad attivita' antiinfiammatoria.
CA2529817C (en) 2003-03-10 2013-02-12 Optimer Pharmaceuticals, Inc. Novel antibacterial agents
JP2006524706A (ja) 2003-04-25 2006-11-02 カイロン コーポレイション 新規なケトライド誘導体
US20050014706A1 (en) 2003-07-14 2005-01-20 Kanakeshwari Falzari Method of treating tuberculosis
US7457520B2 (en) 2003-07-24 2008-11-25 Time Warner Cable, Inc. Technique for providing a virtual digital video recorder service through a communications network
US20060116336A1 (en) 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
WO2005105821A2 (en) 2004-04-28 2005-11-10 Alembic Limited Process for the preparation of telithromycin
WO2006080954A1 (en) 2004-07-28 2006-08-03 Ranbaxy Laboratories Limited Ketolide derivatives as antibacterial agents
CA2591746A1 (en) * 2004-12-21 2006-06-29 Pfizer Products Inc. Macrolides
US20080113926A1 (en) 2005-01-14 2008-05-15 Zrinka Ivezic 9A-Carbamoyl-Y-Aminopropyl- And 9A-Thiocabamoyl-Y-Aminopropyl-Azalides With Antimalarial Activity
WO2007039914A2 (en) 2005-10-06 2007-04-12 Alembic Limited Novel polymorphs of telithromycin
US20070167382A1 (en) * 2005-11-15 2007-07-19 Nina Finkelstein Crystalline and amorphous forms of telithromycin
WO2007060627A2 (en) 2005-11-23 2007-05-31 Ranbaxy Laboratories Limited Use of macrolide derivatives for treating acne
DOP2006000268A (es) 2005-12-22 2007-07-31 Pfizer Prod Inc Agentes antibacterianos
CN101129383B (zh) 2006-08-25 2014-04-02 天津和美生物技术有限公司 含氨基糖苷类抗生素的抗生素复方
US7742562B2 (en) * 2007-06-27 2010-06-22 Accuray Incorporated Lower-torso assembly of a treatment couch useable in an X-ray environment
AU2008316830B2 (en) 2007-10-25 2016-03-17 Cempra Pharmaceuticals, Inc. Process for the preparation of macrolide antibacterial agents
WO2009053259A1 (en) * 2007-10-25 2009-04-30 Sandoz Ag Process for the production of telithromycin
WO2010048600A1 (en) * 2008-10-24 2010-04-29 Cempra Pharmaceuticals, Inc. Methods for treating resistant diseases using triazole containing macrolides
PL2544537T3 (pl) 2010-03-10 2017-10-31 Cempra Pharmaceuticals Inc Pozajelitowe preparaty antybiotyków makrolidowych
HRP20160168T1 (hr) * 2010-03-22 2016-03-25 Cempra Pharmaceuticals Inc Kristalne forme makrolida i njihova uporaba

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017081953A (ja) * 2010-03-22 2017-05-18 センプラ ファーマシューティカルズ，インコーポレイテッド マクロライドの結晶形、およびその使用

Also Published As

Publication number Publication date
KR20130056226A (ko) 2013-05-29
JP2017081953A (ja) 2017-05-18
IL222018B (en) 2019-05-30
US20190040096A1 (en) 2019-02-07
AU2011232627A1 (en) 2012-10-18
RU2012144614A (ru) 2014-04-27
CN103080122A (zh) 2013-05-01
JP2013522367A (ja) 2013-06-13
EP2550286A4 (en) 2013-10-02
US8975386B2 (en) 2015-03-10
US8759500B2 (en) 2014-06-24
HRP20160168T1 (hr) 2016-03-25
MX2012010895A (es) 2013-02-15
KR102006200B1 (ko) 2019-08-01
KR20180101643A (ko) 2018-09-12
MY162411A (en) 2017-06-15
CA2793884A1 (en) 2011-09-29
HK1177937A1 (en) 2013-08-30
AU2016203986A1 (en) 2016-06-30
EP2550286B1 (en) 2015-12-09
EP3009442A1 (en) 2016-04-20
EP3009442B1 (en) 2019-06-19
MX361413B (es) 2018-12-05
RU2650883C2 (ru) 2018-04-18
CN108570083A (zh) 2018-09-25
US20130252915A1 (en) 2013-09-26
NZ602544A (en) 2014-11-28
JP6121387B2 (ja) 2017-04-26
DK2550286T3 (en) 2016-02-29
EP2550286A1 (en) 2013-01-30
SI2550286T1 (sl) 2016-04-29
JP2020002168A (ja) 2020-01-09
WO2011119604A1 (en) 2011-09-29
JP2015063536A (ja) 2015-04-09
CA2793884C (en) 2019-09-10
AU2011232627B2 (en) 2016-03-17
US20160244472A1 (en) 2016-08-25
BR112012023950A2 (pt) 2016-07-05
AU2016203986B2 (en) 2016-10-06
US20130018008A1 (en) 2013-01-17
PL2550286T3 (pl) 2016-07-29
ES2564097T3 (es) 2016-03-17

Similar Documents

Publication Publication Date Title
JP5711352B2 (ja) マクロライドの結晶形、およびその使用
WO2014006576A1 (en) Pharmaceutical compositions comprising rifaximin and amino acids, preparation method and use thereof
CN102256951B (zh) 结晶水合物、药物组合物及其用途
US9593117B2 (en) Crystalline form of N,N-dicyclopropyl-4-(1,5-dimethyl-1H-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide for the treatment of myeloproliferative disorders
US9598413B2 (en) Crystalline form of N,N-dicyclopropyl-4-(1,5-dimethyl-1H-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-D]pyrrolo[2,3-B]pyridine-7-carboxamide for the treatment of myeloproliferative disorders
HK1182115A (en) Crystalline forms of a macrolide, and uses therefor
US20160130272A1 (en) Crystalline forms of n,n-dicyclopropyl-4-(1,5-dimethyl-1h-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboximide for the treatment of myeloproliferative disorders
CN107474057B (zh) (5-(2-腈基苄基)-4,5,6,7-四氢噻吩并[3,2-c]吡啶-2-基)乙酸酯盐酸盐的晶型及其制备方法和用途
HK1221229A1 (en) Crystalline forms of a macrolide, and uses therefor
HK1221229B (en) Crystalline forms of a macrolide, and uses therefor
HK1177937B (en) Crystalline forms of a macrolide, and uses therefor
WO2014193866A1 (en) Crystalline form of n,n-dicyclopropyl-4-(1,5-dimethyl-1 h-pyrazol-3-ylamino)-6-ethyl-1 -methyl-1,6-dihydroimidazo[4,5- d]fy rrolo[2,3-b]pyridine-7-carboxamide for the treatment of myeloproliferative disorders
CN108117570A (zh) 一种替诺福韦艾拉酚胺半富马酸盐的结晶及其制备方法
WO2025032197A1 (en) Crystalline form of 5-((3r,5s)-3-amino-5-trifluoromethyl-piperidin-1-yl)-quinoline-8-carbonitrile
HK40036995A (en) Crystals of glycyrrhizic acid derivatives, crystalline compositions, pharmaceutical compositions and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140328

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20140328

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20140414

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140428

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140723

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140819

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20141114

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20141114

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20150107

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150303

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150305

R150 Certificate of patent or registration of utility model

Ref document number: 5711352

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250